Fissolo Nicolás, Schaedelin Sabine, Villar Luisa M, Lünemann Jan D, Correale Jorge, Rejdak Konrad, Schwab Nicholas, Vilaseca Andreu, Held Friederike, García-Merino Antonio, Bittner Stefan, Trojano María, Furlan Roberto, Tumani Hayrettin, Pérez-Miralles Francisco, Rosenstein Igal, Galimberti Daniela, Álvarez-Bravo Gary, Thouvenot Eric, Llufriu Sara, Khoury Samia J, Hoepner Robert, Martínez-Yélamos Sergio, Hegen Harald, Drulovic Jelena, Téllez-Lara Neus, Khalil Michael, Oechtering Johanna, Pérez-Sempere Ángel, Rodríguez-Antigüedad Alfredo, Enrique-Martínez José, Strijbis Eva, Killestein Joep, Eichau Sara, Colombo Elena, Schaller-Nagengast Jonas, Midaglia Luciana, Sánchez-López Antonio J, Monreal Enric, Chan Andrew, Paul Friedemann, Rovira Àlex, Tintoré Mar, Lycke Jan, Zipp Frauke, Hemmer Bernhard, Kuhle Jens, Montalban Xavier, Comabella Manuel, Zettl Uwe K, Falk Simon, Gutiérrez Lucía, Gasior Magda, Veiga González José Luis, Ferrer Roser, Quiroga-Varela Ana, Bachhuber Franziska, Costa-Frossard Lucienne
Servei de Neurologia and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron. Universitat Autònoma de Barcelona, Barcelona, Spain.
Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) - ISCIII, Madrid, Spain.
JAMA Neurol. 2025 Jun 2. doi: 10.1001/jamaneurol.2025.1481.
Understanding the risk factors for symptom development will allow clinicians to stratify people with radiologically isolated syndrome (pwRIS) more effectively and tailor their management strategies accordingly.
To identify prognostic factors at radiologically isolated syndrome (RIS) diagnosis associated with the development of multiple sclerosis (MS) symptoms.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was performed in samples collected between July 2004 and September 2022 and included 33 MS centers. All pwRIS who meet the 2017 McDonald criteria for dissemination in space with a sample collected near the diagnostic magnetic resonance imaging were included. No patients who met eligibility criteria were excluded. The data were analyzed from July 2024 to November 2024.
Body fluid biomarkers and environmental factors in pwRIS.
The main outcome was the development of MS symptoms. Analyses involved univariable and multivariable Cox proportional hazards models, including age, sex, and treatment following RIS diagnosis, as additional independent variables.
The study included 273 pwRIS (mean age, 38.6 [SD 11.6] years; 207 women [75.8%] and 66 men [24.2%]) with a median follow-up of 5.0 [IQR, 2.5-7.7] years. A total of 101 pwRIS developed MS symptoms (37.0%). The presence of immunoglobulin G oligoclonal bands (OBs) (hazard ratio [HR], 5.09; 95% CI, 2.36-10.97; P < .001), immunoglobulin M OBs (HR, 2.58; 95% CI, 1.61-4.14; P < .001), and a κ free light chain index of 6.1 or more (HR, 2.79; 95% CI, 1.37-5.67; P = .005) were associated with MS symptoms. High cerebrospinal fluid neurofilament light chain (NfL) levels (HR, 1.31; 95% CI, 1.18-1.45; P < .001) and high serum NfL z scores (HR, 1.42; 95% CI, 1.16-1.72; P = .005) were also associated with an increased risk of MS symptoms. In contrast, high anti-cytomegalovirus titers (HR, 0.59; 95% CI, 0.38-0.93; P = .02) and high ultraviolet radiation exposure in the year before (HR, 0.52; 95% CI, 0.37-0.74; P < .001) and the year after (HR, 0.54, 95% CI, 0.38-0.75; P < .001) diagnosis reduced the risk of MS symptoms. For all these prognostic factors, the multivariable analysis yielded similar results. The combination of high serum NfL z scores and positive immunoglobulin G OBs conferred a 5-year risk of clinical symptoms of 58.3% (95% CI, 45.9-67.9). This risk increased to 81.6% (95% CI, 60.9-91.4) in pwRIS who were younger and positive for immunoglobulin M OBs.
The study elucidates the prognostic factors that significantly impact the risk of developing MS symptoms in pwRIS at diagnosis, thereby, enhancing the potential for tailored clinical interventions.
了解症状发展的风险因素将使临床医生能够更有效地对放射性孤立综合征患者(pwRIS)进行分层,并据此调整管理策略。
确定放射性孤立综合征(RIS)诊断时与多发性硬化症(MS)症状发展相关的预后因素。
设计、地点和参与者:这项队列研究在2004年7月至2022年9月期间收集的样本中进行,包括33个MS中心。所有符合2017年McDonald空间播散标准且在诊断性磁共振成像附近采集样本的pwRIS均被纳入。符合纳入标准的患者均未被排除。数据于2024年7月至2024年11月进行分析。
pwRIS中的体液生物标志物和环境因素。
主要结局是MS症状的出现。分析涉及单变量和多变量Cox比例风险模型,将年龄、性别和RIS诊断后的治疗作为额外的独立变量。
该研究纳入了273例pwRIS(平均年龄38.6[标准差11.6]岁;207名女性[75.8%]和66名男性[24.2%]),中位随访时间为5.0[四分位间距,2.5 - 7.7]年。共有101例pwRIS出现了MS症状(37.0%)。免疫球蛋白G寡克隆带(OBs)的存在(风险比[HR],5.09;95%置信区间,2.36 - 10.97;P <.001)、免疫球蛋白M OBs(HR,2.58;95%置信区间,1.61 - 4.14;P <.001)以及κ游离轻链指数≥6.1(HR,2.79;95%置信区间,1.37 - 5.67;P = 0.005)与MS症状相关。高脑脊液神经丝轻链(NfL)水平(HR,1.31;95%置信区间,1.18 - 1.45;P <.001)和高血清NfL z评分(HR,1.42;95%置信区间,1.16 - 1.72;P = 0.005)也与MS症状风险增加相关。相比之下,高抗巨细胞病毒滴度(HR,0.59;95%置信区间,0.38 - 0.93;P = 0.02)以及诊断前一年(HR,0.52;95%置信区间,0.37 - 0.74;P <.001)和诊断后一年(HR,0.54,95%置信区间,0.38 - 0.75;P <.001)的高紫外线辐射暴露降低了MS症状的风险。对于所有这些预后因素,多变量分析得出了相似的结果。高血清NfL z评分和免疫球蛋白G OBs阳性的组合使5年临床症状风险达到58.3%(95%置信区间,45.9 - 67.9)。在年龄较小且免疫球蛋白M OBs阳性的pwRIS中,这一风险增加到81.6%(95%置信区间,60.9 - 91.4)。
该研究阐明了在诊断时对pwRIS发生MS症状风险有显著影响的预后因素,从而增强了进行针对性临床干预的可能性。